Phantom dosimetry and cancer risks estimation undergoing 6 MV photon beam by an Elekta SL-25 linac

Bladder Cancer
20/06/2020

Khabaz R. Appl Radiat Isot 2020.

ABSTRACT

The High-energy linear accelerator (linac) is a valuable tool and the most commonly used devices for external beam radiation treatments in subjects suffer from cancer. To estimate the dose deposited in several organs of a female patient due to pelvic irradiation by an Elekta SL-25 linac in 6 MV photon beam mode, the MCNPX code is used considering the most details of linac. The equivalent dose in different organs is computed according to the face down position (prone) of MIRD and UFRO phantoms.


The data obtained using MCNPX show that the received dose in all commons organs of MIRD and UFRO phantoms is 535.73 and 433.09 mSv/Gyx, respectively. The risks of second cancer incidence and mortality during radiotherapy treatment are compared between MIRD and UFRO phantoms. The results indicated that bladder has the maximum risk of secondary cancer incidence risk of 142.85 and 135.34 per 105 persons based on MIRD and UFRO phantoms, respectively; while the total risk is about 1 in 163 and about 1 in 101 in these phantoms.